Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

August 31, 2023 updated by: AstraZeneca

A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.

Each participant will be assigned randomly to a treatment arm, which could be different strengths of the active treatment or a placebo which does not contain active treatment. Both Participants and investigators will be masked to the treatment assignment.

Approximately 152 participants will take part in this study. There is a 4 weeks screening period to determine eligibility. After eligibility is confirmed, participants will receive investigational drug or placebo during the 16 weeks treatment period. This is then followed by an 8-week follow-up period.

Study Type

Interventional

Enrollment (Actual)

148

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Box Hill, Australia, 3128
        • Research Site
      • Carlton, Australia, 3053
        • Research Site
      • East Melbourne, Australia, 3002
        • Research Site
      • Fremantle, Australia, 6160
        • Research Site
      • Berlin, Germany, 10117
        • Research Site
      • Dresden, Germany, 01307
        • Research Site
      • Hamburg, Germany, 20246
        • Research Site
      • Mahlow, Germany, 15831
        • Research Site
      • Bialystok, Poland, 15-453
        • Research Site
      • Kielce, Poland, 25-355
        • Research Site
      • Poznan, Poland, 60-681
        • Research Site
      • Skierniewice, Poland, 96-100
        • Research Site
      • Wroclaw, Poland, 50-566
        • Research Site
      • Łódź, Poland, 90-436
        • Research Site
      • Alcobendas, Spain, 28100
        • Research Site
      • Leganés, Spain, 28915
        • Research Site
      • Sevilla, Spain, 41003
        • Research Site
      • Corby, United Kingdom, NN18 9EZ
        • Research Site
      • High Wycombe, United Kingdom, HP11 2QW
        • Research Site
      • Kenilworth, United Kingdom, CV8 1JD
        • Research Site
      • Northwood, United Kingdom, HA6 2RN
        • Research Site
      • Romford, United Kingdom, RM1 3PJ
        • Research Site
      • Shipley, United Kingdom, BD18 3SA
        • Research Site
      • Sidcup, United Kingdom, DA14 6LT
        • Research Site
      • Wokingham, United Kingdom, RG40 1XS
        • Research Site
    • Alabama
      • Birmingham, Alabama, United States, 35209
        • Research Site
    • California
      • Santa Monica, California, United States, 90404
        • Research Site
    • Florida
      • Jacksonville, Florida, United States, 32256
        • Research Site
      • Miami, Florida, United States, 33180
        • Research Site
      • Orlando, Florida, United States, 32806
        • Research Site
    • Louisiana
      • Baton Rouge, Louisiana, United States, 70808
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, United States, 28277
        • Research Site
    • Oklahoma
      • Tulsa, Oklahoma, United States, 74136
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, United States, 02903
        • Research Site
    • South Carolina
      • Spartanburg, South Carolina, United States, 29303
        • Research Site
    • Tennessee
      • Memphis, Tennessee, United States, 38119
        • Research Site
    • Texas
      • San Antonio, Texas, United States, 78229
        • Research Site
      • San Antonio, Texas, United States, 78213
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 63 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 18 to 65 years inclusive at the time of consent.
  • Body mass index between 19.0 and 40.0 kg/m2 inclusive.
  • Documented history of chronic AD, for at least 1 year prior to screening Visit 1.
  • Meets at minimum 1 of the criteria, as follows:

    • History of inadequate response to topical medications for AD
    • Subject intolerance to treatment with topical medications for AD, or
    • Topical medications are otherwise medically inadvisable
  • AD that affects ≥ 10% of the body surface area (BSA).
  • An EASI score of ≥ 12 at Visit 1 and ≥ 16 at Visit 3 (Day 1).
  • An IGA score of ≥ 3.

Exclusion Criteria:

  • Any active medical or psychiatric condition, or other reason, that would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
  • Any other clinically relevant abnormal findings from physical examination (including vital signs and electrocardiogram [ECG]) or from safety laboratory analysis.
  • Active dermatologic conditions that might confound the diagnosis of AD or would interfere with the assessment of the skin.
  • Known active allergic or irritant contact dermatitis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MEDI3506 at dose level 1
Participant will receive multiple doses of MEDI3506 at dose level 1.
multiple doses
Experimental: MEDI3506 at dose level 2
Participant will receive multiple doses of MEDI3506 at dose level 2.
multiple doses
Experimental: MEDI3506 at dose level 3
Participant will receive multiple doses of MEDI3506 at dose level 3.
multiple doses
Placebo Comparator: Placebo
Participant will receive multiple doses of Placebo
multiple doses

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent Change From Baseline to Week 16 in EASI Score
Time Frame: Week 16
The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model.
Week 16

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Subjects Achieving a 90% Reduction From Baseline in EASI Score at Week 16
Time Frame: Week 16
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 90% reduction from baseline in EASI score.
Week 16
Percentage of Subjects Achieving a 75% Reduction From Baseline in EASI Score at Week 16
Time Frame: Week 16
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 75% reduction from baseline in EASI score.
Week 16
Percentage of Subjects Achieving a 50% Reduction From Baseline in EASI Score at Week 16
Time Frame: Week 16
To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 50% reduction from baseline in EASI score.
Week 16
Percentage of Subjects Achieving an IGA of 0 (Clear) or 1 (Almost Clear) With at Least a 2 Grade Reduction From Baseline Score at Week 16
Time Frame: Week 16
The IGA allows investigators to assess overall AD disease severity at 1 given time point and consists of a 5-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease).
Week 16
Percentage of Subjects Achieving a Reduction of ≥ 3 From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS
Time Frame: Week 16
Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.
Week 16
Change From Baseline to Week 16 in Weekly Mean of Daily Peak Pruritus NRS
Time Frame: Week 16
Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.
Week 16
Change From Baseline to Week 16 in Weekly Mean of Daily Peak Skin Pain NRS
Time Frame: Week 16
Skin pain (ie, worst skin pain experienced in the previous 24 hours) assessed using an NRS (0 to 10) with 0 = no pain and 10 = worst imaginable pain. The daily assessments were summarised as a weekly mean.
Week 16
SCORAD: Percent Change From Baseline to Week 16
Time Frame: Week 16
SCORAD is a clinical tool for assessing the severity of AD that evaluates the extent and intensity of AD lesions, in addition to subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.
Week 16
Change From Baseline to Week 16 in Percentage Body Surface Area (BSA) Affected by AD
Time Frame: Week 16
Change in percentage of body surface area (BSA) affected by AD from baseline at week 16.
Week 16
Change From Baseline to Week 16 in DLQI
Time Frame: Week 16
The Dermatology Life Quality Index (DLQI) is a 10-item, patient- completed, health-related quality of life assessment of dermatology conditions with a recall period of 1 week. Each item is scored on a 4-point Likert scale with 0 = not at all ⁄not relevant, 1 = a little, 2 = a lot, and 3 = very much. The score from each item is summed, and the maximum total score is 30 while the minimum score is 0. Higher score means highest (adverse) effect on participant's life.
Week 16
Patient Description of Atopic Dermatitis or Eczema From Patient Global Impression of Severity at Week 16
Time Frame: Week 16
The Patient Global Impression of Severity (PGI-S) is a tool that allows patients to rate the severity of a condition over the past 7 days with response options of "No symptoms", "Very mild", "Mild", "Moderate", "Severe" and "Very severe".
Week 16
Change From Baseline to Week 16 in POEM
Time Frame: Week 16
The Patient-Oriented Eczema Measure (POEM) is a 7-item questionnaire for assessing disease symptoms including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping occurring in the past week. Each item is scored on a 5-point scale with 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = every day. The total POEM score is calculated by summing the score of each item resulting in a maximum of 28 and a minimum of 0, with higher values indicating severe disease
Week 16
Change From Baseline to Week 16 in 5-D Itch
Time Frame: Week 16
The 5-D Itch Scale is a questionnaire consisting of 5 items used specifically to measure the course of itch by asking for the degree, duration, disability and distribution of the pruritus within the last 2 weeks. The scores from each item are summed, with maximum score of 25 and minimum score of 5. Higher score represent worse outcome
Week 16
Occurrence of Adverse Events
Time Frame: up to 24 weeks
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
up to 24 weeks
Oral or Tympanic Temperature Taken During Vital Signs Assessment
Time Frame: Baseline, week 16 and week 24
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Baseline, week 16 and week 24
Systolic Blood Pressure Taken During Vital Signs Assessment
Time Frame: Baseline, week 16 and week 24
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Baseline, week 16 and week 24
Heart Rate Taken During Vital Signs Assessment
Time Frame: Baseline, week 16 and week 24
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Baseline, week 16 and week 24
Respiratory Rate Collected During Vital Signs Assessment
Time Frame: Baseline, week 16 and week 24
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Baseline, week 16 and week 24
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology
Time Frame: up to 24 weeks
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
up to 24 weeks
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry
Time Frame: up to 24 weeks
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
up to 24 weeks
Number of Participants With Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis
Time Frame: up to 24 weeks
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
up to 24 weeks
Heart Rate (Beats/Min) Recorded on ECGs
Time Frame: Baseline, week 16 and week 24
Collectively with other ECG parameters are used t assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Baseline, week 16 and week 24
QT (Miliseconds) Recorded on ECGs
Time Frame: Baseline, week 16 and week 24
Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Baseline, week 16 and week 24
Number of Participants With Investigator's Overall ECGs Evaluations, e.g. Normal/Abnormal and Their Clinical Significance
Time Frame: Week 16 and week 24
Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Week 16 and week 24
Left Ventricular Ejection Fraction Measured by Echocardiogram
Time Frame: Baseline and week 16
To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.
Baseline and week 16
Serum MEDI3506 Concentration Profiles
Time Frame: Week 16 and week 24
To evaluate the PK of MEDI3506 in adult subjects with moderate-to-severe AD.
Week 16 and week 24
Occurence of Anti-drug Antibody During the Treatment and Follow-up Periods
Time Frame: up to 24 weeks
To evaluate the immunogenicity of MEDI3506 in adult subjects with moderate-to-severe AD.
up to 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 9, 2019

Primary Completion (Actual)

July 21, 2022

Study Completion (Actual)

September 20, 2022

Study Registration Dates

First Submitted

November 4, 2019

First Submitted That Met QC Criteria

December 24, 2019

First Posted (Actual)

December 26, 2019

Study Record Updates

Last Update Posted (Actual)

September 28, 2023

Last Update Submitted That Met QC Criteria

August 31, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD Sharing Time Frame

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD Sharing Access Criteria

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atopic Dermatitis

Clinical Trials on Placebo

3
Subscribe